MUMBAI - India's top drug maker Ranbaxy Laboratories could be ready to team up with Israel's Teva Pharmaceuticals for an "at risk" launch of a generic version of AstraZeneca's heartburn blockbuster Nexium (esomeprazole), following tentative U.S. approval last month, Indian analysts say
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.
Private Company Edition: Catalio raised more than $400m for its fourth health care-focused VC fund, while AN Venture Partners raised $200m for Japan and beyond. In VC financings, among a dearth of mega rounds, Neuron23’s $96.5m series D is the largest round in recent weeks.
After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.
